Valuation: Verastem, Inc.

Market Cap 1.23B 1.1B 1.02B 922M 1.72B 117B 1.74B 12.17B 4.85B 61.16B 4.61B 4.51B 194B P/E 2026 *
-6.24x
P/E 2027 * -7.57x
Enterprise Value 1.04B 932M 862M 780M 1.46B 98.94B 1.48B 10.3B 4.1B 51.77B 3.9B 3.82B 164B EV / Sales 2026 *
9.33x
EV / Sales 2027 * 7.71x
Free-Float
99.19%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-0.50%
1 week+9.28%
Current month+25.03%
1 month+29.54%
3 months+61.56%
6 months+84.34%
Current year+30.38%
1 week 9.14
Extreme 9.14
10.25
1 month 6.7
Extreme 6.7
10.25
Current year 3.43
Extreme 3.43
10.25
1 year 3.43
Extreme 3.43
10.82
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
39.6
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 2023-07-31
Director of Finance/CFO 39 2022-10-30
Chief Tech/Sci/R&D Officer - 2024-04-17
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 2023-07-31
Director/Board Member 69 2017-05-02
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Sell

Chief Financial Officer

-2,566 0.0042%
10/1/26 Sell

Chief Executive Officer

-44,121 0.0717%
9/21/26 Sell

Chief Financial Officer

-55 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%+9.28%+13.73%+61.82% 1.23B
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+1.91%-0.03%+26.78%+56.10% 44.75B
+2.30%-3.21%+18.05%+100.44% 41.62B
+0.38%-3.88%+221.02%+917.66% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +3.88%+0.44%+47.85%+151.77% 38.17B
Weighted average by Cap. +3.03%-0.26%+46.98%+160.13%

Financials

2026 *2027 *
Net sales 111M 99.86M 92.32M 83.61M 156M 10.6B 158M 1.1B 440M 5.55B 418M 409M 17.61B 159M 143M 132M 120M 223M 15.16B 226M 1.58B 629M 7.93B 597M 585M 25.18B
Net income -170M -153M -141M -128M -239M -16.23B -242M -1.69B -673M -8.49B -639M -626M -26.96B -179M -160M -148M -134M -251M -17.01B -254M -1.77B -705M -8.9B -670M -656M -28.26B
Net Debt -188M -169M -156M -141M -264M -17.93B -267M -1.87B -744M -9.38B -707M -692M -29.79B -
Projected Income Statement - Annual - Verastem, Inc.
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
26-10-28 $10.07 -0.30% 1,400,001
26-10-27 $10.10 +1.00% 4,708,399
26-10-26 $10.00 -0.40% 4,289,252
26-10-23 $10.04 -0.20% 3,762,126
26-10-22 $10.06 +9.23% 5,947,460
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Verastem, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
10.10USD
Average target price
17.22USD
Spread / Average Target
+70.52%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Verastem, Inc.
  1. Stock Market
  2. Stocks
  3. VSTM Stock